Drugmaker Merck recently won FDA approval for a new drug to treat pulmonary arterial hypertension (PAH), a rare heart condition that thickens blood vessel walls and causes heart failure, according to CNN Health. The drug, which Merck plans to market under the name Winrevair, is designed to slow or stop disease progress, and could prolong the lifespans of PAH sufferers. Without treatment, most PAH patients survive about two to three years after diagnosis.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.